Despite the ending of its partnership with pharmaceutical giant Pfizer, Madison-based Deltanoid Pharmaceuticals remains confident about prospects for its lead drug.
“It’s a very safe compound and it looks like it might work,” said UW-Madison Professor Hector DeLuca, who led the team that developed 2MD, a potentially revolutionary osteoporosis drug that is the first to show the ability to stimulate new bone formation, rather than just prevent bone loss.